“A NOVEL RNA INTERFERENCE THERAPY TO REDUCE CARDIOVASCULAR RISK BY LOWERING LIPOPROTEIN(A) LEVELS USING THE LEPODISIRAN AGENT”. Journal of Multidisciplinary Sciences and Innovations, vol. 5, no. 03, Mar. 2026, pp. 1550-3, https://doi.org/10.55640/.